Novo Nordisk Inc v. DR Reddy's Laboratories Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Novo Nordisk Inc. (Delaware) and Novo Nordisk A/S (Denmark)
  • Defendant: Dr. Reddy's Laboratories, Ltd. (India) and Dr. Reddy's Laboratories, Inc. (New Jersey)
  • Plaintiff’s Counsel: Walsh Pizzi Oreilly Falanga LLP
• Case Identification: 1:26-cv-12228, D.N.J., 09/16/2026
• Venue Allegations: Venue is asserted in the District of New Jersey based on Defendant Dr. Reddy's Laboratories, Inc. being incorporated and having a principal place of business in New Jersey, and Defendant Dr. Reddy's Laboratories, Ltd. being a foreign corporation subject to nationwide jurisdiction.
• Core Dispute: Plaintiff alleges that Defendant’s filing of an Abbreviated New Drug Application (ANDA) for a generic version of the WEGOVY® HD drug product infringes three patents related to pharmaceutical compositions of semaglutide and methods of its use for weight management.
• Technical Context: Semaglutide is a GLP-1 receptor agonist, a class of drugs widely used for managing type 2 diabetes and chronic weight management.
• Key Procedural History: This is a Hatch-Waxman action initiated under 35 U.S.C. § 271(e)(2) after Plaintiffs received a Paragraph IV Certification Notice Letter from the Defendants, dated August 4, 2026. The complaint identifies related pending litigation against another generic manufacturer, Novo Nordisk Inc. et al. v. Apotex Inc.

Case Timeline

Date	Event
2017-08-24	U.S. Patent No. 12,214,017 Priority Date
2017-10-12	U.S. Patent No. 12,551,536 Priority Date
2020-02-18	U.S. Patent No. 11,318,191 Priority Date
2022-05-03	U.S. Patent No. 11,318,191 Issued
2025-02-04	U.S. Patent No. 12,214,017 Issued
2026-02-17	U.S. Patent No. 12,551,536 Issued
2026-08-04	DRL Sends Paragraph IV Notice Letter
2026-09-16	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,318,191 - "GLP-1 Compositions and Uses Thereof"

• Patent Identification: U.S. Patent No. 11,318,191, "GLP-1 Compositions and Uses Thereof," issued May 3, 2022.

The Invention Explained

• Problem Addressed: The patent's background section notes a desire to develop single-use semaglutide compositions that are stable and, critically, comfortable for patients to self-administer, referencing prior art that reported pain upon injection for other phenol-free peptide formulations U.S. Patent 11,318,191, col. 1:21-34
• The Patented Solution: The patent discloses a liquid pharmaceutical composition of semaglutide containing very low or no phenol and a specific concentration of sodium chloride (above 6.4 mg/mL) U.S. Patent 11,318,191, abstract The inventors state they "surprisingly" found that such compositions "have improved properties in relation to injection pain experience" U.S. Patent 11,318,191, col. 1:60-65
• Technical Importance: This technology aims to improve patient compliance and user experience for a self-administered injectable drug by reducing injection site pain, a common barrier to adherence.

Key Claims at a Glance

• The complaint asserts at least independent claims 1 and 15 Compl. ¶¶49, 55
• Independent Claim 1 is a composition claim with the following essential elements:
  • A liquid pharmaceutical composition comprising 0.5 to 10 mg/mL semaglutide
  • 0.0% (w/w) to 0.1% (w/w) phenol
  • and 8.2 to 8.9 mg/mL sodium chloride
• Independent Claim 15 is a method of use claim covering the administration of the composition of claim 1 for treating a group of diseases including diabetes and obesity.
• The complaint reserves the right to assert additional claims Compl. ¶25

U.S. Patent No. 12,214,017 - "GLP-1 Compositions and Uses Thereof"

• Patent Identification: U.S. Patent No. 12,214,017, "GLP-1 Compositions and Uses Thereof," issued February 4, 2025.

The Invention Explained

• Problem Addressed: The patent background states that GLP-1 peptides are "prone to develop lack of stability in liquid solutions," which may include physical or chemical instability U.S. Patent 12,214,017, col. 1:24-30
• The Patented Solution: The patent describes a liquid pharmaceutical composition of semaglutide that specifically "does not contain phenol" and is administered parenterally U.S. Patent 12,214,017, col. 2:18-21 The composition is further defined as an aqueous solution with specific excipients (a buffer or isotonic agent) and a pH between 7.0 and 7.8, a formulation designed to enhance stability U.S. Patent 12,214,017, col. 13:30-44
• Technical Importance: Improving the chemical and physical stability of injectable peptide drugs is a significant challenge in pharmaceutical development, as it is critical for ensuring product shelf-life, safety, and consistent therapeutic potency.

Key Claims at a Glance

• The complaint asserts at least independent claims 1 and 8 Compl. ¶¶78, 84
• Independent Claim 1 is a composition claim with the following essential elements:
  • A liquid pharmaceutical composition comprising semaglutide
  • wherein said composition (a) does not contain phenol
  • and (b) is administered parenterally
  • and (c)(i) is an aqueous solution comprising at least 60% (w/w) water or (ii) further comprises a buffer or an isotonic agent
  • wherein the semaglutide is in the range of 0.01 mg/ml to 10.0 mg/ml
  • and wherein the pH of the composition is in between 7.0 and 7.8
• Independent Claim 8 is a method of use claim covering the administration of the composition of claim 1 for treating obesity.
• The complaint reserves the right to assert additional claims Compl. ¶26

U.S. Patent No. 12,551,536 - "Semaglutide in Medical Therapy"

• Patent Identification: U.S. Patent No. 12,551,536, "Semaglutide in Medical Therapy," issued February 17, 2026.
• Technology Synopsis: The patent addresses the need for improved medical therapies for weight management, particularly those that manage the common gastrointestinal side effects of GLP-1 receptor agonists U.S. Patent 12,551,536, col. 2:21-34 The invention is a method of use involving the administration of a specific high-dose weekly regimen of semaglutide (2.0-10.0 mg) which is described as providing an improved ratio of body weight reduction to adverse events like nausea U.S. Patent 12,551,536, col. 2:35-41
• Asserted Claims: At least independent claim 1 Compl. ¶107
• Accused Features: The use of the Defendant's ANDA Product according to its proposed label, which allegedly instructs for subcutaneous administration of semaglutide at a dosage up to 7.2 mg once weekly, which falls within the claimed range Compl. ¶¶110, 112

III. The Accused Instrumentality

• Product Identification: The accused instrumentality is Defendant’s Abbreviated New Drug Application (ANDA) No. 221759 Product ("DRL's ANDA Product"), which is a proposed generic version of semaglutide injection, 7.2 mg/0.75 mL, for subcutaneous use Compl. ¶18
• Functionality and Market Context: The complaint alleges that DRL's ANDA Product is an injectable aqueous solution of semaglutide intended for use in weight management, sold in a single-dose pen Compl. ¶¶16, 18 The complaint further alleges that the product's formulation and proposed label "essentially copies" Novo Nordisk's brand-name product WEGOVY® HD and its associated New Drug Application (NDA), as is typical for a generic drug seeking approval via the ANDA pathway Compl. ¶¶58, 87, 116 The product targets the significant commercial market for GLP-1 receptor agonist-based weight-loss therapies Compl. ¶¶10, 12 The complaint provides the structural formula of semaglutide, the active ingredient in the accused product Compl. ¶15, Fig. 1

IV. Analysis of Infringement Allegations

11,318,191 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A liquid pharmaceutical composition comprising 0.5 to 10 mg/mL semaglutide	DRL's ANDA Product is a 7.2 mg/0.75 mL solution, which corresponds to a concentration of 9.6 mg/mL, falling within the claimed range.	¶50; ¶58	col. 25:53-54
0.0% (w/w) to 0.1% (w/w) phenol	DRL's ANDA Product is alleged to be identical to WEGOVY® HD, which the complaint describes as not containing phenol as an inactive ingredient, thus having 0% phenol.	¶51; ¶58	col. 25:54-55
and 8.2 to 8.9 mg/mL sodium chloride	DRL's ANDA Product is alleged to be identical to WEGOVY® HD, which contains 8.25 mg of sodium chloride per 1 mL of solution, falling within the claimed range.	¶51; ¶58	col. 25:55-56

12,214,017 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A liquid pharmaceutical composition comprising: semaglutide	DRL's ANDA Product is a generic version of semaglutide injection.	¶79; ¶87	col. 13:31-32
wherein said composition (a) does not contain phenol	DRL's ANDA Product is alleged to be identical to WEGOVY® HD, whose formulation does not list phenol as an inactive ingredient.	¶80; ¶87	col. 13:34
and (b) is administered parenterally	DRL's ANDA seeks approval for a product intended for subcutaneous injection.	¶81; ¶87	col. 13:35
and (c)(i) is an aqueous solution comprising at least 60% (w/w) water or (ii) further comprises one or more...excipients...a buffer...	DRL's ANDA Product is alleged to be an aqueous solution identical to WEGOVY® HD, which contains water for injection and disodium phosphate dihydrate, a buffer.	¶80; ¶87	col. 13:36-40
and wherein the semaglutide is in the range of 0.01 mg/ml to 10.0 mg/ml	DRL's ANDA Product has a semaglutide concentration of 9.6 mg/mL, which is within the claimed range.	¶79; ¶87	col. 13:40-42
and wherein the pH of the composition is in between 7.0 and 7.8	DRL's ANDA Product is alleged to be identical to WEGOVY® HD, which has a pH of approximately 7.4.	¶80; ¶87	col. 13:42-44

• Identified Points of Contention:
  • Scope Questions: The infringement allegations for all three patents rely on the assertion that the Defendant's proposed generic product is "identical" or "essentially copies" the formulation and label of the brand-name drug, WEGOVY® HD Compl. ¶¶58, 87, 116 While this forms a basis for literal infringement, the central dispute will likely concern the validity of the patents, which the Defendant challenged in its Paragraph IV certification Compl. ¶22
  • Technical Questions: A key question for the ’191 Patent may be whether the specific combination of low/no phenol and a narrow sodium chloride range (8.2 to 8.9 mg/mL) was non-obvious for reducing injection pain. For the ’017 Patent, a technical question may be whether creating a stable, phenol-free formulation of semaglutide was non-obvious to a person of ordinary skill in the art. For the ’536 Patent, a core question will be whether the claimed dosage regimen (2.0-10.0 mg weekly) demonstrated an unexpected improvement in the ratio of weight loss to side effects.

V. Key Claim Terms for Construction

For the ’191 Patent:

• The Term: "comprising"
• Context and Importance: This standard transitional phrase is typically interpreted as open-ended, meaning the composition can include other unlisted ingredients. However, its scope can be a point of contention. Practitioners may focus on this term because if Defendant's product includes additional excipients not listed in claim 1, the defense could argue these additions alter the composition's fundamental character, potentially taking it outside the claim's scope, though this is a difficult argument to win.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The use of "comprising" itself is strong evidence for a standard, open-ended interpretation.
  • Evidence for a Narrower Interpretation: The specification frequently uses the more restrictive phrases "consisting of" and "consisting essentially of" to describe various embodiments (e.g., ’191 Patent, col. 3:5-46). A defendant may argue this pattern suggests the inventors intended a more limited scope for "comprising" than is typical, or that the invention is properly defined by the "consisting of" embodiments.

For the ’017 Patent:

• The Term: "does not contain phenol"
• Context and Importance: This term appears absolute and is central to the infringement allegation against a product that is also alleged to be phenol-free. Practitioners may focus on this term because its interpretation—whether it means an absolute absence or merely "substantially free"—could be critical if the accused product contains trace, non-functional amounts of phenol.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader (more absolute) Interpretation: The plain language of claim 1, "does not contain phenol," is an unambiguous negative limitation suggesting a complete absence is required.
  • Evidence for a Narrower (less absolute) Interpretation: The abstract of the '017 Patent describes compositions "comprising no more than 0.01% (w/w) phenol," which a defendant could argue provides context that "does not contain" should be interpreted as meaning below a certain functional or detectable threshold, rather than a strict zero.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that upon approval, the Defendant will induce infringement of the method of use claims (e.g., claim 15 of the '191 Patent, claim 8 of the '017 Patent, and claim 1 of the '536 Patent). This allegation is based on the assertion that the Defendant’s proposed product label will "essentially cop[y]" the WEGOVY® label and therefore instruct and encourage physicians and patients to use the drug in an infringing manner Compl. ¶¶60, 89, 116
• Willful Infringement: The complaint asserts that the Defendant has "actual knowledge" of the Asserted Patents, citing the Paragraph IV certification Compl. ¶¶47, 76, 105 It further alleges that the Defendant's non-infringement and invalidity positions are "devoid of an objective good faith basis," which lays the groundwork for a claim of enhanced damages under 35 U.S.C. § 284 and attorneys' fees under § 285 Compl. ¶¶71, 100, 126

VII. Analyst’s Conclusion: Key Questions for the Case

• A central question for the case will be one of validity and non-obviousness: will the Defendant be able to demonstrate by clear and convincing evidence that the specific formulation parameters claimed in the '191 and '017 patents—such as the narrow sodium chloride range for pain reduction or the complete removal of phenol for stability—were obvious advancements to a person of ordinary skill in the art, rather than patentable inventions?
• A second key issue will be one of induced infringement, particularly for the method-of-use claims in the '536 Patent: does the proposed label for the generic product, alleged to be a copy of the brand-name label, provide instructions that are sufficiently specific to direct prescribers to administer the drug in the high-dose regimen required by the patent claims, thereby establishing the requisite specific intent for inducement?
• A final question will relate to claim construction: can the absolute term "does not contain phenol" in the '017 Patent be interpreted to permit trace, non-functional amounts, potentially creating a non-infringement defense, or does the plain language require a complete absence of the compound?